Rain Enhancement Technologies Holdco, Inc. (“RET Holdco” or the “Company”) (Nasdaq: RAIN, RAINW), an emerging company developing rainfall generation technology, today announced that Randy Seidl has been appointed as Chief Executive Officer (“CEO”) of RET Holdco and of its wholly-owned subsidiary, Rain Enhancement Technologies, Inc. (“RET”). Seidl has served as Co-Chief Executive Officer and a member of the Board of Directors since January 2, 2025.
Pathos AI, Inc. (“Pathos”) today announced that it has, through its wholly owned subsidiary WK Merger Sub, Inc. (“Merger Sub”), successfully completed its tender offer to acquire all outstanding shares of the common stock of Rain Oncology Inc. (Nasdaq: RAIN) (“Rain”) for $1.16 per share in cash plus one contingent value right per share (each, a “CVR”), which CVR shall represent the right to receive potential payments pursuant to the terms and subject to the conditions of the Contingent Value Rights Agreement, dated as of January 26, 2024, by and among Pathos, Merger Sub, Equiniti Trust Company, LLC, and Fortis Advisors LLC.
Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Rain Oncology Inc. (NasdaqGS: RAIN) to Pathos AI, Inc. Under the terms of the proposed transaction, shareholders of Rain will receive $1.16 in cash plus a non-tradeable contingent value right for potential cash payments of up to approximately $0.17, for each share of Rain that they own. KSF is seeking to determine whether this consideration and the process that led to it are adequate, or whether the consideration undervalues the Company.
BALA CYNWYD, Pa., Jan. 04, 2024 (GLOBE NEWSWIRE) -- Brodsky & Smith reminds investors of the following investigations. If you own shares and wish to discuss the investigation, contact Jason Brodsky (jbrodsky@brodskysmith.com) or Marc Ackerman (mackerman@brodskysmith.com) at 855-576-4847. There is no cost or financial obligation to you.
BALA CYNWYD, Pa., Dec. 26, 2023 (GLOBE NEWSWIRE) -- Brodsky & Smith reminds investors of the following investigations. If you own shares and wish to discuss the investigation, contact Jason Brodsky (jbrodsky@brodskysmith.com) or Marc Ackerman (mackerman@brodskysmith.com) at 855-576-4847. There is no cost or financial obligation to you.
Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Rain Oncology Inc. (NasdaqGS: RAIN) to Pathos AI, Inc. Under the terms of the proposed transaction, shareholders of Rain will receive $1.16 in cash plus a non-tradeable contingent value right for potential cash payments of up to approximately $0.17, for each share of Rain that they own. KSF is seeking to determine whether this consideration and the process that led to it are adequate, or whether the consideration undervalues the Company.
BALA CYNWYD, Pa., Dec. 18, 2023 (GLOBE NEWSWIRE) -- Brodsky & Smith reminds investors of the following investigations. If you own shares and wish to discuss the investigation, contact Jason Brodsky (jbrodsky@brodskysmith.com) or Marc Ackerman (mackerman@brodskysmith.com) at 855-576-4847. There is no cost or financial obligation to you.
Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of Rain Oncology Inc. (NASDAQ: RAIN) to Pathos AI, Inc. for $1.16 in cash per share plus a non-tradeable contingent value right for potential cash payments of up to approximately $0.17 per share is fair to Rain shareholders.
San Diego, CA -- (SBWIRE) -- 10/19/2023 -- An investigation was announced for current long-term investors in shares of Rain Oncology Inc. (NASDAQ:RAIN) concerning potential breaches of fiduciary duties by certain directors of Rain Oncology Inc.
The Dow Jones closed slightly higher on Friday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision.
WHY: NEW YORK, NY - (NewMediaWire) - September 12, 2023 - Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Rain Oncology Inc. (NASDAQ: RAIN) between July 20, 2021 and May 19, 2023, both dates inclusive (the “Class Period”), of the important September 12, 2023 lead plaintiff deadline.
The Law Offices of Frank R. Cruz reminds investors of the upcoming September 12, 2023 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who acquired Rain Oncology Inc. (“Rain” or the “Company”) (NASDAQ: RAIN) securities between July 20, 2021 and May 19, 2023, inclusive (the “Class Period”).
Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, reminds investors that a class action lawsuit has been filed against Rain Oncology, Inc. (“Rain” or the “Company”) (NASDAQ: RAIN) in the United States District Court for the Northern District of California on behalf of all persons and entities who purchased or otherwise acquired Rain securities between July 20, 2021, and May 19, 2023, both dates inclusive (the “Class Period”). Investors have until September 12, 2023 to apply to the Court to be appointed as lead plaintiff in the lawsuit.
NEW YORK, Sept. 08, 2023 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Rain Oncology Inc. (NASDAQ: RAIN) between July 20, 2021 and May 19, 2023, both dates inclusive (the “Class Period”), of the important September 12, 2023 lead plaintiff deadline.
NEW YORK, Sept. 06, 2023 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf of stockholders of Baxter International, Inc. (NYSE: BAX), Rain Oncology, Inc. (NASDAQ: RAIN), and Danaher Corporation (NYSE: DHR). Stockholders have until the deadlines below to petition the court to serve as lead plaintiff. Additional information about each case can be found at the link provided.
San Diego, CA -- (SBWIRE) -- 09/06/2023 -- The Shareholders Foundation announced that a deadline is coming up on September 12, 2023 in the lawsuit filed for certain investors of Rain Oncology Inc. (NASDAQ: RAIN).
